2023
Clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in “Long-COVID19”
Fesharaki-Zadeh A, Lowe N, Arnsten A. Clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in “Long-COVID19”. Neuroimmunology Reports 2023, 3: 100154. DOI: 10.1016/j.nerep.2022.100154.Peer-Reviewed Original ResearchN-acetylcysteineCognitive deficitsΑ2A-adrenoceptor agonistsPrefrontal cortexCOVID19 infectionPlacebo-controlled trialOpen-label treatmentCommon side effectsExecutive functionPFC connectionsBrain fogAcid blockadeLabel treatmentHypotensive episodesGuanfacine treatmentNMDA receptorsPatient brieflySide effectsClinical experienceGuanfacineCognitive impairmentPatientsPrefrontal connectivityDemonstrate efficacyPrefrontal function
1995
Guanfacine Treatment of Comorbid Attention-Deficit Hyperactivity Disorder and Tourette's Syndrome: Preliminary Clinical Experience
CHAPPELL P, RIDDLE M, SCAHILL L, LYNCH K, SCHULTZ R, ARNSTEN A, LECKMAN J, COHEN D. Guanfacine Treatment of Comorbid Attention-Deficit Hyperactivity Disorder and Tourette's Syndrome: Preliminary Clinical Experience. Journal Of The American Academy Of Child & Adolescent Psychiatry 1995, 34: 1140-1146. PMID: 7559307, DOI: 10.1097/00004583-199509000-00010.Peer-Reviewed Original ResearchConceptsYale Global Tic Severity ScaleAttention deficit hyperactivity disorderTourette syndromeContinuous Performance TestHyperactivity disorderOpen-label studyCommon side effectsSeverity of motorComorbid attention deficit hyperactivity disorderSafe alternative therapySignificant decreaseTic Severity ScalePreliminary clinical experienceMajority of subjectsConners' Parent Rating ScaleTransient sedationControlled TrialsAlternative therapiesSedative effectsGuanfacine treatmentPhonic ticsSeverity ScaleSide effectsStimulant medicationTic severity